Regencell Bioscience (NASDAQ:RGC) Trading Up 12% – Still a Buy?

Shares of Regencell Bioscience Holdings Limited (NASDAQ:RGC) shot up 12% on Tuesday . The stock traded as high as $5.67 and last traded at $5.71. 120,853 shares changed hands during mid-day trading, a decline of 63% from the average daily volume of 323,120 shares. The stock had previously closed at $5.10.

Analyst Ratings Changes

RGC has been the subject of several research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Regencell Bioscience in a report on Wednesday, June 24th. Wall Street Zen cut Regencell Bioscience from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Regencell Bioscience presently has an average rating of “Sell”.

Regencell Bioscience Stock Down 1.3%

The firm’s 50 day moving average is $14.98 and its 200-day moving average is $23.80.

Regencell Bioscience (NASDAQ:RGC) last posted its earnings results on Friday, May 8th. The company reported ($0.00) EPS for the quarter.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Squarepoint Ops LLC bought a new position in shares of Regencell Bioscience in the 2nd quarter valued at approximately $1,701,000. BNP Paribas Financial Markets acquired a new position in Regencell Bioscience during the second quarter valued at approximately $768,000. XTX Topco Ltd acquired a new position in Regencell Bioscience during the third quarter valued at approximately $598,000. Hudson Bay Capital Management LP acquired a new position in Regencell Bioscience during the fourth quarter valued at approximately $275,000. Finally, Vident Advisory LLC raised its position in shares of Regencell Bioscience by 65.7% in the fourth quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock valued at $629,000 after purchasing an additional 11,866 shares during the period. Institutional investors and hedge funds own 0.13% of the company’s stock.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.